Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1983 1
1991 1
1998 5
1999 4
2000 4
2001 9
2002 10
2003 17
2004 33
2005 28
2006 38
2007 34
2008 31
2009 35
2010 27
2011 29
2012 23
2013 32
2014 35
2015 34
2016 21
2017 7
2018 4
2019 7
2020 5
2021 10
2022 10
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

449 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Schettini F, et al. Cancer Treat Rev. 2022 Dec;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub 2022 Sep 28. Cancer Treat Rev. 2022. PMID: 36202026 Free article. Review.
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. ...
Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algor …
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE. Pujol P, et al. Eur J Cancer. 2021 Mar;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub 2021 Feb 10. Eur J Cancer. 2021. PMID: 33578357 Free article. Review.
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. ...The group followed a methodology based on specific formal guidelines d …
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility …
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe A, Sud M, Cuoco MS, Labes D, Gritsch S, Zollinger DR, Ortogero N, Beechem JM, Petur Nielsen G, Chebib I, Nguyen-Ngoc T, Montemurro M, Cote GM, Choy E, Letovanec I, Cherix S, Wagle N, Sorger PK, Haynes AB, Mullen JT, Stamenkovic I, Rivera MN, Kadoch C, Wucherpfennig KW, Rozenblatt-Rosen O, Suvà ML, Riggi N, Regev A. Jerby-Arnon L, et al. Nat Med. 2021 Feb;27(2):289-300. doi: 10.1038/s41591-020-01212-6. Epub 2021 Jan 25. Nat Med. 2021. PMID: 33495604 Free PMC article.
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we studied the cancer-immune interplay in SyS using an integrative approach that combines single-cell RNA sequencing (scRNA-seq), spatial …
Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18-SSX fusion, and is characterized by low T cell infiltration. Here, we st …
[Pregnancy after cancer: for whom and when?].
Margulies AL, Selleret L, Zilberman S, Nagarra IT, Chopier J, Gligorov J, Berveiller P, Ballester M, Darai E, Chabbert-Buffet N. Margulies AL, et al. Bull Cancer. 2015 May;102(5):463-9. doi: 10.1016/j.bulcan.2015.03.012. Epub 2015 Apr 24. Bull Cancer. 2015. PMID: 25917345 Free article. Review. French.
Planning a pregnancy for patients with a history of cancer, including breast cancer, is a clinical situation that becomes more and more common. Several specific items are to be discussed: decrease of fertility after cancer treatment, fertility preservation op …
Planning a pregnancy for patients with a history of cancer, including breast cancer, is a clinical situation that becomes more …
[Fertility and cancer].
Poirot C, Sitbon L, Fortin A, Berthaut I, Jaudi S, Anastacio A, Prades M. Poirot C, et al. Presse Med. 2013 Nov;42(11):1513-20. doi: 10.1016/j.lpm.2013.06.019. Epub 2013 Nov 1. Presse Med. 2013. PMID: 24184281 Review. French.
Cancer of the pancreas.
Andre T, Hammel P, Lacaine F, Palazzo L, Becouarn Y, Mornex F. Andre T, et al. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S75-2S80. Gastroenterol Clin Biol. 2006. PMID: 17151566 Free article. Review. No abstract available.
[Lung cancer and HIV infection].
Lavolé A, Toper C, Belmont L, Ruppert AM, Wislez M, Cadranel J. Lavolé A, et al. Rev Mal Respir. 2014 Feb;31(2):133-41. doi: 10.1016/j.rmr.2013.07.009. Epub 2013 Nov 25. Rev Mal Respir. 2014. PMID: 24602680 Review. French.
In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in terms of both incidence and mortality. ...
In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in te …
[Pancreatic cancer].
Huguet F, Orthuon A, Touboul E, Marseguerra R, Mornex F. Huguet F, et al. Cancer Radiother. 2010 Nov;14 Suppl 1:S94-102. doi: 10.1016/S1278-3218(10)70012-3. Cancer Radiother. 2010. PMID: 21129675 French.
Currently, the use of radiotherapy for patients with pancreatic cancer is controversial. In adjuvant setting, the standard treatment is six months of chemotherapy with FUFOL or gemcitabine. ...The aims of this work are to precise the radio-anatomical particularities, the p …
Currently, the use of radiotherapy for patients with pancreatic cancer is controversial. In adjuvant setting, the standard treatment …
[Molecular characteristics of lung cancer].
Bernaudin JF. Bernaudin JF. Bull Cancer. 2010 Nov;97(11):1323-35. doi: 10.1684/bdc.2010.1211. Bull Cancer. 2010. PMID: 21051316 Free article. Review. French.
While no real improvement in the long term survival has been obtained in lung cancer, during this decade a significant improvement in cancer control has been obtained by biology driven targeted therapy as with anti EGFR tyrosine kinase. ...A new molecular classifica …
While no real improvement in the long term survival has been obtained in lung cancer, during this decade a significant improvement in …
Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy.
Huguet F, Mukherjee S, Javle M. Huguet F, et al. Clin Oncol (R Coll Radiol). 2014 Sep;26(9):560-8. doi: 10.1016/j.clon.2014.06.002. Epub 2014 Jul 4. Clin Oncol (R Coll Radiol). 2014. PMID: 25001636 Review.
At the time of diagnosis, around 20% of patients with pancreatic cancer present at a resectable stage, 50% have metastatic disease and 30% have locally advanced tumour, non-metastatic but unresectable because of superior mesenteric artery or coeliac encasement. Despite adv …
At the time of diagnosis, around 20% of patients with pancreatic cancer present at a resectable stage, 50% have metastatic disease an …
449 results